JIANMIN GROUP(SH:600976)2024-01-15 07:37Group 1: Company Performance - The company achieved a revenue of 3.118 billion yuan in the first three quarters of the year, representing a year-on-year growth of 10.95% [1] - The net profit reached 415 million yuan, with a year-on-year increase of 31.85% [1] - The overall business remains stable, with ongoing promotion of the OTC product strategy [1] Group 2: Product Sales and Expectations - The sales of the proprietary product "Jianpi Shengxue Granules" are expected to grow, targeting pediatric and adult iron deficiency anemia [2] - Sales of "Longmu" products are recovering, with 30-bag specifications performing normally, while 60-bag specifications are slower due to different sales channels [2] - "Qirui Weishu Capsules," an innovative traditional Chinese medicine, is currently performing well in sales after entering the medical insurance directory [2] Group 3: Future Development Plans - The company plans to enhance its product matrix and brand positioning in 2024, focusing on the "Longmu" and "Jianmin" brands [2] - Continuous growth is anticipated for prescription line products, with new varieties like "Badu Shengji San" and "Qirui Weishu Capsules" expected to contribute positively [3] - Increased investment in R&D is planned, focusing on innovative traditional Chinese medicine and addressing common pediatric diseases [3]